Evidence map›Paper›PMID 40597357›Full record

ArticleChinese medicine2025

Decoding the anti-thrombotic effects of leonurine: a multimodal approach combining TCM repositioning and mTOR signaling.

Xin Dong, Shuaibing Jia, Leifeng Zhang, Yong Liang, Jianhua Zhang, Yi Zhun Zhu

Abstract read
In one paragraph

Article in Chinese medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xin Dong *Faculty of Innovation Engineering, Macau University of Science and Technology, Avenida Wai Long, Taipa, Macau, 999078, China.
Shuaibing Jia *Medical Engineering Technology and Data Mining Institute, Zhengzhou University, 100 Science Avenue, Zhengzhou, 450000, China.
Leifeng ZhangMedical Engineering Technology and Data Mining Institute, Zhengzhou University, 100 Science Avenue, Zhengzhou, 450000, China.
Yong LiangPeng Cheng Laboratory, Shenzhen, 518055, China. yongliangresearch@gmail.com.
Jianhua ZhangSchool of Pharmacy, Macau University of Science and Technology, Avenida Wai Long, Taipa, Macau, 999078, China. petermails@zzu.edu.cn.
Yi Zhun ZhuSchool of Pharmacy, Macau University of Science and Technology, Avenida Wai Long, Taipa, Macau, 999078, China. yzzhu@must.edu.mo.

Funding

Key Scientific Research Project of Henan Province Colleges and Universities 22A416002Macau Science and Technology Development fund 003/2022/ALCMacau Science and Technology Development fund 0092/2022/A2Macau Science and Technology Development fund 0144/2022/A3)Macau Science and Technology Development fund FDCT (0012/2021/AMJShenzhen-Hong Kong-Macao Science and Technology Fund SGDX20220530111203020the General Project of National Natural Science Foundation of China 222300420538the major key project of Peng Cheng Laboratory under grant PCL2023A09the TianYuan funds for Mathematics of the National Science Foundation of China 12326604
6 · The paper itself

Abstract

backgroundAs a natural small molecule compound, Leonurine have great potential for application in the treatment of cardiovascular diseases. However, there is still a gap in the treatment of thrombosis with Leonurine.

methodsA multimodal heterogeneous network is constructed using ETCM and STRING databases, integrating herbs, ingredients, targets and diseases. A reposition model constructed by random walk and random forests is used to predict the relationship between Leonurine and diseases. In addition, network pharmacology, molecular docking and molecular dynamics are used as computer-aided methods to confirm the target of Leonurine. Finally, CCK-8 assay, Flow cytometry, Western Blotting, and mouse experiments are used to validate the therapeutic potential of Leonurine from the perspective of biological wet experiments.

resultsFirstly, based on the accurate prediction results evaluated by indicators, Leonurine is evaluated to have potential therapeutic effects on thrombotic diseases. Through computer-aided methods, mTOR is identified as a potential regulatory factor and may have a similar regulatory mechanism to the marketed drug Everolimus. Experimental results demonstrate that Leonurine reduces thrombotic cell apoptosis and promotes endothelial cell proliferation by inhibiting mTOR signaling. Additionally, in vivo studies show decrease mTOR expression in thrombotic tissues following Leonurine treatment.

conclusionsThese findings underscore mTOR's critical role in mediating Leonurine's anti-thrombotic effects, supported by both computational and experimental evidence. The study provides a foundation for the application of TCM-derived compounds in modern medicine, particularly in thrombosis treatment.

Indexed as

Heterogeneous networkIngredients-diseases relationshipLeonurinemTORRepositioningThrombosisTraditional Chinese medicine (TCM)

Identifiers

PMID40597357
PMCPMC12220451

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.